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Enhancing Humoral Responses 
Against HIV Envelope Trimers 
via Nanoparticle Delivery with 
Stabilized Synthetic Liposomes
Talar Tokatlian1, Daniel W. Kulp2,3,4, Andrew A. Mutafyan1, Christopher A. Jones1, 
Sergey Menis2,3, Erik Georgeson2,3, Mike Kubitz2,3, Michael H. Zhang1, Mariane B. Melo  1, 
Murillo Silva1, Dong Soo Yun1, William R. Schief2,3,5,7 & Darrell J. Irvine1,3,6,7,8
An HIV vaccine capable of eliciting durable neutralizing antibody responses continues to be an 
important unmet need. Multivalent nanoparticles displaying a high density of envelope trimers may be 
promising immunogen forms to elicit strong and durable humoral responses to HIV, but critical particle 
design criteria remain to be fully defined. To this end, we developed strategies to covalently anchor a 
stabilized gp140 trimer, BG505 MD39, on the surfaces of synthetic liposomes to study the effects of 
trimer density and vesicle stability on vaccine-elicited humoral responses in mice. CryoEM imaging 
revealed homogeneously distributed and oriented MD39 on the surface of liposomes irrespective of 
particle size, lipid composition, and conjugation strategy. Immunization with covalent MD39-coupled 
liposomes led to increased germinal center and antigen-specific T follicular helper cell responses and 
significantly higher avidity serum MD39-specific IgG responses compared to immunization with soluble 
MD39 trimers. A priming immunization with liposomal-MD39 was important for elicitation of high 
avidity antibody responses, regardless of whether booster immunizations were administered with 
either soluble or particulate trimers. The stability of trimer anchoring to liposomes was critical for 
these effects, as germinal center and output antibody responses were further increased by liposome 
compositions incorporating sphingomyelin that exhibited high in vitro stability in the presence of 
serum. Together these data highlight key liposome design features for optimizing humoral immunity to 
lipid nanoparticle immunogens.
Despite recent global declines in HIV infection and AIDS-related deaths as a result of the increasing availability 
of anti-retroviral drugs, HIV remains a widespread pandemic with over 36 million living with HIV/AIDS as of 
20161. To finally eliminate new HIV infections a prophylactic vaccine remains an urgent need. It is likely that a 
successful vaccine against HIV-1 will need to induce broadly neutralizing antibodies (bnAbs) that neutralize 
diverse strains of the virus2–4. Isolated bnAbs from rare individuals who are able to naturally control infection 
have been shown to target conserved regions of the HIV envelope spike on HIV, which is comprised of 3 copies of 
the subunits gp120 and gp41 non-covalently assembled into trimers. Passive transfer of bnAbs into non-human 
primates protects from challenge with simian immunodeficiency virus expressing HIV-1 envelopes5–8. In order to 
elicit such antibodies by immunization, recombinant env immunogens recapitulating the structure of the native 
trimer have been avidly pursued. These efforts have led to the generation of recombinant soluble trimers that pre-
serve native neutralizing conformational epitopes targeted by many known bnAbs but which sequester epitopes 
commonly recognized by non-neutralizing antibodies9–14. A particularly successful strategy for generation of 
native-like gp140 trimers has been through the design of so-called SOSIP immunogens, fully cleaved trimers 
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stabilized by gp120-gp41 disulfide bonds and mutation of critical residues promoting interactions between 
gp41 subunits9,15,16. Additional design modifications have further improved the antigenic profiles of native-like 
trimers13,17,18.
Recent successes in employing SOSIP trimers to elicit for the first time autologous tier 2 neutralizing anti-
body titers in rabbits19 and non-human primates20 have spurred enthusiasm for exploring new avenues to further 
promote humoral responses to these immunogens. One such avenue is the use of nanoparticles for the multiva-
lent display of trimers, which could promote B cell activation and engagement of low affinity B cell precursors 
through enhanced B cell receptor (BCR) crosslinking. It has been widely demonstrated that particulate display 
of antigens, in the forms of virus-like particles, synthetic nanoparticle platforms, or protein/peptide nanopar-
ticles and nanocarriers, can significantly boost humoral responses and the development of protective antibody 
responses compared to monomeric immunogens21–26. In the context of HIV vaccine development, both protein- 
and lipid-based nanoparticles have previously been reported and shown to enhance humoral responses to trimer 
immunogens27–29. Alternatively, unilamellar liposomes have a well-established track record as safe and effec-
tive drug delivery vehicles in humans, as demonstrated by currently approved liposome-based drugs (e.g. Doxil, 
Myocet, and Marqibo for cancer therapy, DepoDur for pain management, Ambisome for treatment of fungal 
infections, and several others) and formerly approved vaccines (e.g. Epaxal® for hepatitis A and Inflexal® V 
for influenza; both were discontinued in 2014 due to manufacturing quality issues)30. Given their ability to be 
prepared in a range of particle sizes and capacity to be conjugated to any antigen of interest, we and others have 
demonstrated that stabilized trimers can be densely conjugated to the surface of unilamellar liposomes using both 
non-covalent18,31 and covalent20,32 coupling strategies.
Here we explored properties of a liposomal nanoparticle platform that allows for both oriented and stable 
conjugation of HIV envelope trimers. Trimer-conjugated liposomes improved both germinal center (GC) B cell 
and trimer-specific T follicular helper (Tfh) cell responses, resulting in significantly higher trimer-specific anti-
body titers and overall higher avidity antibody production relative to immunization with soluble MD39 SOSIP 
trimers. Additional optimization of the liposome composition to improve stability in the presence of serum was 
shown to even further enhance germinal center responses in mice. These results define key design criteria for the 
generation of effective lipid nanoparticle immunogens for HIV and other infectious diseases.
Results
Synthesis of liposome-based HIV trimer virus-like particles. To generate highly multivalent nano-
particles that could in theory be employed for delivery of any trimer immunogen while meeting criteria for clin-
ical translation (scalable manufacturability, safety/biodegradability30), we focused on unilamellar liposomes. As 
model immunogens, we employed a SOSIP trimer known as BG50516, or a stabilized version of this trimer called 
MD39, which incorporates multiple mutations designed to limit sampling of non-native conformations, such as 
those that expose the V3 loop, and to increase expression and thermal stability13,18. We previously demonstrated 
that mixing of MD39 trimers containing C-terminal histags on each gp140 subunit with liposomes functional-
ized with Ni-NTA headgroup lipids leads to oriented anchoring of the immunogen to the vesicle surfaces18. To 
produce high density trimer-liposomes with a high overall coupling efficiency (~95%), we found the optimal ratio 
of MD39-6xHis:Ni-NTA during coupling to be approximately 1:40. However, despite the availability of 3 histags 
per trimer for Ni-NTA anchoring, when incubated with 10% mouse serum for 24 hours, these non-covalently 
anchored trimers were completely dissociated (Fig. 1A and Supplementary Fig. S1), similar to what has been 
previously described by others33–35. To address this issue, liposomes were prepared with 5 mol% maleimide-func-
tionalized lipids (MPB) in addition to 5 mol% Ni-NTA lipids, and MD39 trimers were modified to introduce 
a single free cysteine residue immediately adjacent to each histag at the C-terminus of the gp41-ectodomain 
trimer subunits (Fig. 1B). Efficient trimer coupling was obtained by including both Ni-NTA (to rapidly cap-
ture the trimers on the vesicle surfaces) and MPB (to subsequently covalently react with the C-terminal trimer 
cysteines). CryoEM imaging revealed similar morphologies for liposomes loaded with covalently- or non-cova-
lently-anchored trimers, and revealed oriented attachment of trimers across the liposome surfaces (Fig. 1C and 
Supplementary Fig. S2A,B). Further titrating the MD39:lipid ratio during the initial conjugation step allowed 
for the density of trimer coupled to the liposome surfaces to be readily controlled (Fig. 1D and Supplementary 
Fig. S2C). Except where otherwise noted, we focused our analyses on liposomes decorated with the maximum 
density of trimer (~14 nm center-to-center spacing between trimers on the liposome surfaces) with a mean vesicle 
diameter of ~150 nm (Supplementary Fig. S2D). Importantly, MD39 trimer antigenicity, determined by ELISA 
analysis of monoclonal antibody binding to liposomes captured on plates coated with the CD4 binding site-di-
rected antibody VRC01 (Fig. 1E), was similar between the initial MD39 protein and liposome-conjugated trimer 
regardless of coupling strategy. MD39-liposomes showed high levels of binding by bnAbs (PGT121 (V3 glycan 
specific bnAb), PGT145 (V1/V2 glycan specific bnAb), PGT151 (gp120/gp41 interface specific bnAb), VRC01 
(CD4 binding site specific bnAb)) and minimal binding by non-nAbs (B6 (CD4 binding site specific non-nAb), 
4025 or 39 F (both V3 specific non-nAbs); Fig. 1F,G). As expected, introduction of covalent linkages via MBP 
lipids enhanced the retention of trimer on liposomes exposed to serum, with ~60% of the initially loaded tri-
mer retained following incubation with 10% serum for 24 hr (Fig. 1A). Trimers retained after the rapid initial 
loss (<1 day) then remained stably attached for at least one week in serum (Fig. 1H). Thus, covalent anchor-
ing allowed trimers to be loaded at high density on liposomes, retaining a native-like antigenicity profile, while 
improving serum stability of the particulate immunogen.
We previously demonstrated that liposomes conjugated with a high density of engineered germline-targeting 
trimers were able to activate B cells expressing a germline B cell receptor with very low affinity (KD > 10 µM) 
for gp140 at 1000-fold lower concentrations compared to soluble trimers18, suggesting a substantial advantage 
for nanoparticulate immunogens in a primary immune response. However, repeated booster immunizations as 
commonly employed in HIV vaccine studies will promote the development of B cells with high affinity for the 
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antigen, and it is unclear if particulate display will still be important in this setting. To shed light on this issue, 
we assessed the activation of B cells expressing the high-affinity CD4 binding site antibody VRC01 in a calcium 
flux assay. Despite the higher affinity of VRC01 for the MD39 trimer (KD ~ 124 nM)13, MD39-liposomes triggered 
stronger calcium signaling than soluble trimer across a range of concentrations, eliciting a greater peak signaling 
intensity at all trimer concentrations tested (Fig. 2A–C). Addition of MD39-liposomes to VRC01 B cells led to 
similarly strong activation of calcium signaling whether trimers were conjugated by Ni-NTA/histag binding alone 
or covalent coupling (Fig. 2D). We tested the importance of membrane rigidity by preparing liposomes with 
DSPC (Tm = 55 °C) or DMPC (Tm = 24 °C) phospholipids, but these particles exhibited identical B cell stimulation 
(Fig. 2D). Activation of B cells by nanoparticle-displayed trimers was influenced by trimer density, with more 
sustained signaling triggered by liposomes bearing high-density trimer (Fig. 2E). Thus, high-density liposome 
display enhances B cell activation at the single cell level.
Figure 1. Synthesis of covalently-anchored trimer-liposomes. (A) Serum stability analysis comparing the 
fraction of MD39 trimer retained on liposomes prepared by covalent coupling or Ni-NTA binding following 
24 hours incubation in 10% mouse serum (blue bars) at 37 °C (n = 3–4; ****p < 0.0001, t test). (B) Covalent 
coupling strategy. (C) Representative cryoEM images of non-covalent and covalently coupled MD39 liposomes. 
Scale bar = 100 nm. (D) Trimer densities on 150 nm-diameter liposomes and center-to-center spacing as a 
function of coupling strategy and relative trimer concentration during liposome conjugation. (E) Schematic of 
antigenic profile analysis on intact liposomes compared to soluble trimers. bnAb (PGT121, PGT145, PGT151, 
VRC01) and non-nAb (B6, 39 F, 4025) binding profiles of (F) soluble MD39 trimers and (G) non-covalent and 
covalent MD39 liposomes. (H) Retention of MD39 on covalent liposomes over time in PBS (black) or 10% 
mouse serum (blue) at 37 °C (n = 3).
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Immunogenicity of covalent MD39-coupled liposomes in mice. We next compared in detail 
the humoral responses elicited by soluble trimers vs. covalently-anchored liposomal trimers. Balb/c mice 
were primed on day 0 and boosted at 6 weeks with 1 µg of MD39 trimer (soluble or on liposomes) and 
ISCOMATRIX36, and serum IgG responses were analyzed 3 weeks post-boost. ISCOMATRIX adjuvant, which 
was first described by Morein et al.37, is a 40 nm cage-like nanoparticle composed of lipids, cholesterol, and Quil 
A saponin and posses both innate and adaptive TLR-independent immune modulation and antigen delivery 
characteristics38. Immunization with MD39 trimer-liposomes or soluble MD39 trimer resulted in comparable 
MD39-6xHis-specific IgG titers (Fig. 3A). However, soluble MD39 induced a high level of irrelevant anti-histag 
antibodies, whereas histag-directed responses were undetectable in 7/10 liposome-immunized animals (Fig. 3B). 
We speculate this altered specificity is due to steric sequestration of the trimer histags against the liposome sur-
face. Consistent with a histag-dominated response to the soluble trimer, ELISA analysis of serum IgG binding 
to MD39 trimers lacking histags revealed a 4.1-fold mean difference in trimer-specific response by immuniza-
tion with covalent liposomes compared to soluble trimer, with many of the soluble trimer-immunized animals 
showing no bona fide trimer-specific response (Fig. 3C, p = 0.0138). These responses were sustained over several 
months, despite only the single booster immunization after 6 weeks (Supplementary Fig. S3). Immunization 
with non-covalent liposomes bearing Ni-NTA-anchored trimers similarly produced strong antibody titers 
(Supplementary Fig. S4A). However, as expected due to their instability in the presence of serum proteins, these 
liposomes also elicited high levels of histag-specific antibodies comparable to immunization with soluble trimers 
(Supplementary Fig. S4B). In addition to the synthetic protein tag, the V3 loop is a highly immunodominant 
epitope that is not exposed in trimers with a native-like, closed conformation17,19. V3-loop specific responses were 
not detected in the majority of mice immunized with MD39 (soluble or on covalent liposomes) (Supplementary 
Fig. S5), likely due to the engineered stability of the MD39 trimer13. In contrast, in a separate immunization 
study with wild-type BG505 SOSIP, V3-loop responses were elicited by soluble BG505 immunization, and these 
responses were completely eliminated when BG505 trimer was anchored to liposomes (Fig. 3D).
Measurement of the avidity of antibodies elicited by trimer immunization using a mild urea treatment to dis-
rupt low affinity antigen-antibody interactions during ELISA analysis revealed that soluble trimer immunization 
elicited low-avidity antibody responses in a majority of animals, but liposome delivery elicited significantly higher 
avidity responses (Fig. 3E). One key observation was that this high avidity response was only observed with 
more rigid liposomes comprised mainly of DSPC lipids, while liposomes that were expected to be more fluid and 
containing mainly DMPC were not able to elicit high avidity responses in vivo (Supplementary Fig. S6) despite 
equivalent activation of antigen-specific B cells in vitro (Fig. 2D). Trimer density on the liposome surfaces also 
impacted the magnitude of the humoral response, with the highest IgG responses elicited by maximally-packed 
trimers on the liposome surfaces (Fig. 3F).
Figure 2. Multivalent display of MD39 trimers from liposomes enhances activation of VRC01-expressing 
B cells in vitro. (A–C) Comparison of calcium flux by VRC01-expressing B cells in response to soluble or 
multivalent display of trimers at (A) 5, (B) 1 or (C) 0.2 µg/ml of trimer. (D) Comparison of calcium flux in 
response to multivalent display of trimers on various liposomes at 5 µg/ml of trimer. (E) Extended in vitro 
activation of VRC01-expressing B cells with liposomes with various densities of MD39 trimer at 0.5 µg/ml 
trimer. Center-to-center spacing of trimers on various liposomes denoted within parentheses. Data shown is 
representative of 2–3 separate experiments.
www.nature.com/scientificreports/
5SCIENTIfIC REPORTS |         (2018) 8:16527  | DOI:10.1038/s41598-018-34853-2
Liposomal delivery enhances germinal center responses to trimer immunization. The high 
degrees of somatic hypermutation and unusual structural features characteristic of broadly neutralizing antibod-
ies will likely require highly active and long-lived germinal centers (GCs) to be stimulated by a successful HIV 
vaccine. To assess the impact of liposome delivery on GC responses in vivo, GC B cells in draining inguinal lymph 
nodes were enumerated by flow cytometry at 7 and 21 days following immunization (Fig. 4A). MD39-liposome 
immunization approximately tripled the frequency of GL7+PNA+ germinal center B cells compared to immu-
nization with soluble trimer 7 days after immunization, and sustained this difference at 3 weeks post-prime 
(Fig. 4B). We next enumerated MD39-specific follicular helper T cell (Tfh) responses at the same time points, 
using a recently described activation-induced marker assay (Fig. 4C)39. While differences in total Tfh were signif-
icant at both 7 and 21 days, responses trended toward at least 2-fold more trimer-specific Tfh at any given time 
after immunization with covalent trimer-conjugated liposomes compared to soluble MD39 (Fig. 4D,E). Adjuvant 
alone (Fig. 4B,D,E) or blank liposomes with or without Ni-NTA lipids (Supplementary Fig. S7) elicited no detect-
able GC B cell or Tfh responses above background levels observed in naïve, unimmunized mice. Thus, liposomal 
vaccination enhanced both Tfh and GC B cell induction compared to soluble trimer in primary immunizations.
Particulate priming is especially important for inducing high avidity antibodies. In a primary 
immune response, particulate delivery of immunogens should provide a clear advantage over immunization 
with soluble/monomeric antigen. By contrast, in secondary responses stimulated by booster immunizations, 
Figure 3. MD39-liposomes elicit higher avidity trimer-focused antibody responses compared to soluble 
MD39 trimer immunization. Humoral responses in mice 3 weeks post-boost. Balb/c mice were immunized 
with 1 µg MD39 trimer and 0.2U ISCOMATRIX, and boosted at 6 weeks with the same formulations. Data 
shown contains pooled samples from 2 or 3 replicate experiments with each individual experiment having 
3–5 animals/group. (A) Serum MD39–6xhis-specific titers (n = 8–12 animals/group). (B) Serum 6xhis tag-
specific titers. (C) Serum MD39-specific titers determined by ELISA using non-6xhis tagged MD39 trimers 
to exclude histag-specific responses. (D) Serum V3-specific titers following immunization with 2 µg wild-
type BG505 SOSIP trimers and 1 µg MPLA co-delivered either in soluble form or within non-covalent SOSIP 
liposomes (n = 4 animals/group). (E) Avidity of polyclonal antibodies from immunization with MD39 and 
ISCOMATRIX (from part A). (F) Serum MD39-6xhis-specific titers following immunization with MD39 on 
covalent liposomes at varying surface densities with ISCOMATRIX adjuvant (n = 5 animals/group). X-axis 
denotes average center-to-center trimer spacing on 150 nm liposomes. Dotted line in titer plots denotes limit 
of detection. *p < 0.05, Mann-Whitney test for titers and unpaired t test for avidity. Panel F was analyzed by a 
Kruskal-Wallis test.
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the presence of pre-existing IgM/IgG will lead to the rapid formation of immune complexes of antibodies with 
injected immunogens, potentially converting even soluble antigen into particulates in situ, possibly limiting the 
benefits of nanoparticle delivery for boosting. To assess whether liposomal delivery was more important during 
priming vs. boosting, groups of balb/c mice were immunized with trimer in liposomal form during the prime 
only, the boost only, or during prime and boost, compared to a traditional immunization with trimer in soluble 
form only. As shown in Fig. 5A, MD39-6xHis-specific IgG titers were comparable between all immunization 
groups following booster immunization. However, when the avidities of these IgG responses were compared, 
immunization that included liposomes during priming appeared to exhibit increased binding strength compared 
Figure 4. Trimer-liposomes elicit stronger germinal center responses than soluble trimer immunization. (A) 
Representative flow plots of germinal center B cell populations (parent gate B220+ IgD-low). (B) GL7+ PNA+ 
IgD-low (B220+) GC B cell frequency in draining inguinal lymph nodes at 7 (red) and 21 (blue) days post-
immunization. (C) Representative flow plots of total (CXCR5+ PD1+ with parent gate CD4+ CD44+) Tfh and 
antigen-specific (OX40+ CD25+ PDL1+) Tfh after 18 hour ex-vivo peptide stimulation. Frequencies of (D) total 
and (E) antigen-specific Tfh in draining inguinal lymph nodes at 7 (red) and 21 (blue) days post-immunization. 
Each dot in plots (B,D,E) represents one animal (n = 4–5 animals/group); *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001, ordinary one-way ANOVA with Tukey post-test on each time point.
Figure 5. Liposomal trimer delivery maximizes humoral responses during primary immunization but 
less critical druing booster immunizations. Balb/c mice were immunized with 1 µg MD39 trimer and 0.2U 
ISCOMATRIX, and boosted at 6 weeks with the same formulations. (A) Serum MD39-6xhis-specific IgG titers 
(n = 3–4 animals/group); dotted line denotes limit of detection. (B) Avidity of polyclonal antibodies. Avidity 
was analyzed using independent unpaired t tests for direct comparisons; *p < 0.05.
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to the vaccinations using soluble trimer as the prime (Fig. 5B). Thus, compared to soluble trimers, particulate 
delivery appears to initiate a more effective primary immune response that is sustained post boosting.
Further enhancing liposome stability improves humoral responses. The data discussed above 
demonstrated enhanced GC responses, Tfh priming, and output antibody titers to trimers delivered in liposomal 
vs. soluble form, despite the liposome formulation only exhibiting modest stability in serum in vitro (Fig. 1A). 
Thus, we finally explored whether optimizing the liposomal membrane composition for greater serum stability 
could promote further enhancements in trimer immunogenicity. To this end we tested increasing the amount 
of maleimide-headgroup lipids included in the liposomal bilayers and introducing the hydrogen-bonding lipid 
sphingomyelin and/or the lower-Tm lipid DPPC (Tm = 41 °C) into the liposome bilayers to improve trimer cou-
pling and increase bilayer stability, respectively. It was quantitatively and qualitatively confirmed by ELISA and 
cryoEM, respectively, that overall trimer density was unaffected despite changes in liposome composition. To 
assess the impact of these altered liposome compositions on serum stability, we incubated MD39-liposomes in 
20% mouse serum for 3 days and then separated intact liposomes from free trimer by size exclusion chroma-
tography. This stringent test was used to more closely mimic protein levels in lymphatic fluid40,41. Increasing 
maleimide-lipid content from 5 to 15%, exchanging cholesterol for sphingomyelin, and exchanging DSPC for 
DPPC all incrementally improved the stability of trimer-liposomes in serum, with ~80% trimer retention after 3 
days in 20% mouse serum for the most stable composition (Fig. 6A,B and Supplementary Fig. S8).
Increasing stability of the liposomes correlated with improved early germinal center responses in vivo, 
with covalent trimer-conjugated liposomes containing DPPC and sphingomyelin resulting in significantly 
Figure 6. Optimizing in vitro liposomal trimer serum stability leads to enhanced germinal center and IgG 
responses in vivo. (A,B) Serum stability analysis comparing covalent MD39 trimer conjugated liposomes 
formed with DSPC:Ni-NTA:MPB:cholesterol (61.5:5:5:28.5; blue) or DPPC:Ni-NTA:MPB:sphingomyelin 
(51.5:5:15:28.5; red) after 3 days in 20% mouse serum at 37 °C (n = 3–4; ****p < 0.0001). (A) Size exclusion 
chromatography profile of liposomes and (B) quantification of remaining liposome-associated trimer after 
serum treatment. (C–E) Germinal center responses following immunization with increasingly stabilized trimer-
conjugated liposomes. Frequencies of (C) GL7+ PNA+ IgD-low (B220+) GC B cells, (D) total (CXCR5+ 
PD1+ with parent gate CD4+ CD44+) and (E) antigen-specific (OX40+ CD25+ PDL1+) Tfh in draining 
inguinal lymph nodes 7 days post-immunization (n = 5 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001, 
ordinary one-way ANOVA with Tukey post-test. (F) Serum MD39-specific titers in mice 3 weeks post-boost 
comparing immunization with MD39 trimers either in soluble form or highly stabilized liposomes. Mice were 
immunized with 1 µg MD39 trimer and 5 µg in-house formulated saponin adjuvant, and boosted at 6 weeks 
(n = 10 animals/group). MD39-specific titers were determined by ELISA using non-6xhis tagged MD39 trimers 
to exclude histag-specific responses; dotted line denotes limit of detection. **p < 0.01, Mann-Whitney test.
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higher GC B cell frequencies compared to the original liposome formulation (Fig. 6C). Here soluble trimers or 
trimer-conjugated liposomes were co-injected with an in-house generated formulation of saponin nanoparticles 
in place of ISCOMATRIX (due to the lack of access to commercial ISCOMATRIX at the time of this study). 
Interestingly, frequencies of both total and trimer-specific Tfh remained unchanged as a function of overall lipos-
ome stability (Fig. 6D,E). Given these trends in GC induction, we next compared immunization of the most stable 
DPPC liposome formulation directly with soluble trimers. Stable trimer-conjugated DPPC liposomes elicited sig-
nificantly higher titers (11.6-fold greater) compared with soluble trimers 3 weeks post-boost (Fig. 6F, p = 0.0052), 
a greater relative increase than that observed with the original liposome formulation (Fig. 3C), albeit with a 
slightly modified adjuvant.
Discussion
While the benefits of multivalent antigen delivery for vaccines have been widely documented, studies to eval-
uate nanoparticle delivery of HIV env trimers have only gained momentum within the last few years. Across 
several different platforms, particulate trimer immunogens with increased valency have been shown to trigger 
both germline and mature B cell signaling more strongly compared to soluble gp140 molecules18,32,42, despite 
the inherently trimeric nature of the HIV env complex. Liposomes are an attractive platform for nanoparticle 
delivery of HIV immunogens, as many liposomal products have successfully been translated into the clinic and 
the tunable size of lipid vesicles enables as many as several hundred (300+) trimers to be displayed on a single 
particle, with controllable density. Liposomes decorated with trimers spaced ~14 nm apart were able to strongly 
activate VRC01-expressing B cells in vitro irrespective of liposome composition and trimer conjugation strategy 
(Fig. 2), in agreement with previous reports32. Reduced valency and increased trimer spacing negatively impacted 
B cell activation in vitro, but these trends were not as clearly evident in vivo likely due to the many additional steps 
beyond BCR engagement involved in the immune response in lymphoid tissues. However, immunization with 
liposomes bearing trimers at a nearly close-packed spacing of 14 nm tended to increase antibody titers compared 
to immunization with soluble antigen. These results are directly in line with the understanding that HIV has 
evolved to only express a low number of intact envelope trimer copies (~14/HIV) to evade bivalent binding by 
IgG and limit the rate of broadly neutralizing antibody induction43.
While not fully validated in the context of neutralizing antibody responses for HIV, the current consensus is 
that removal of potentially immunologically distracting, non-neutralizing epitopes may improve responses to 
other more desirable epitopes17,19. Covalent conjugation nearly eliminated recognition of proximal histags and 
potentially helped to maintain trimer stability in vivo, as demonstrated by reduced V3-eptiope specific responses 
for a native BG505 trimer with relatively high V3 exposure compared to MD39 (Fig. 3D). Covalent display of 
trimers also resulted in significantly higher germinal center and sustained antigen-specific Tfh responses. Strong 
Tfh responses are essential in driving high affinity antibody responses in immunization, as exemplified by the 
significantly higher avidity antibody responses that were produced upon immunization with covalent liposome 
coupled trimers. Notably, we found that the nanoparticle form of trimers was most important during the ini-
tial prime immunization, with lower impact during boosting. Yet despite differences in antibody avidity, overall 
antibody titers were not significantly different as immunization with soluble trimers especially resulted in highly 
variable titer responses.
Pauthner and Havenar-Daughton and colleagues recently showed induction of neutralizing antibodies 
in non-human primates (NHPs) which was attributed to the use of stabilized trimers in combination with an 
improved immunization schedule and route of administration20. Unexpectedly, however, multivalent display of 
trimers in this study minimally increased MD39 SOSIP-specific titers and did not improve induction of neutral-
izing responses. As revealed by the present studies, this finding was likely a result of poor overall particle stability 
in the presence of serum proteins. Additional studies by Wyatt and colleagues showed covalent conjugation of 
JRFL trimers to liposomes could induce high avidity neutralizing antibodies in some NHPs44. As such, a better 
understanding of how stable, multivalent delivery of HIV env trimers triggers early germinal center responses 
and initiates induction of high affinity antibodies will be critical for future vaccine design.
Covalent conjugation of MD39 trimers to liposomes composed of 61.5% DSPC, 28.5% cholesterol, 5% 
Ni-NTA, and 5% MPB improved serum stability significantly compared to Ni only liposomes (~60% reten-
tion compared to ~5% after 1 day in 10% serum). While these liposomes clearly demonstrated improvements 
over immunization with soluble trimers in mice, they may still not have been stable enough to fully capture the 
potential of high-density display of HIV env trimers to engage antigen-specific B cells in vivo and induce strong 
neutralizing responses in NHPs20. We finally tested several liposome formulations (Supplementary Fig. S8) and 
each lipid component was determined to be critical in controlling either overall liposome stability or conjuga-
tion between the trimer and liposome. Increasing the maleimide content from 5 to 15% improved trimer reten-
tion in serum, although increasing past 15% did not provide further enhancements (Supplementary Fig. S8A). 
Importantly, 5% Ni-NTA lipids were still necessary to maintain overall coupling efficiency (>95%). Other strat-
egies to improve coupling, such as introducing an optimal length linker between the trimer and the reactive end 
group as described by Bale et al.32, could also be useful, although they were not tested in this study. Cholesterol 
has been widely demonstrated to tighten phospholipid bilayers, especially in combination with gel-phase phos-
pholipids45,46. However, exchanging cholesterol for sphingomyelin significantly improves bilayer stability by intro-
ducing inter- and intra-molecular hydrogen bonding46. Finally, exchanging DSPC for DPPC further enhanced 
the stability of sphingomyelin-containing liposomes, perhaps due to improved compatibility of DPPC and sphin-
gomyelin. Importantly, these substitutions resulted in highly stable trimer-liposome particles (final composition: 
51.5% DPPC, 28.5% sphingomyelin, 5% Ni-NTA, and 15% MPB) that exhibited improved early GC responses and 
significantly higher overall trimer-specific titers.
As described above, several findings in this study are in agreement with those reported by Bale and col-
leagues32, further validating the potential for covalently conjugated trimer-liposomes for an HIV vaccine. BCR 
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engagement at the cellular level is significantly enhanced through high multivalency of trimer antigens, leading 
to stronger germinal center responses and higher antigen-specific antibody titers (trimer+, V3−, 6xHis−) over 
immunization with soluble trimers in the context of ISCOMATRIX adjuvant. While the longevity of the antibody 
response was not reported by Bale et al. they did show that multiple immunizations continued to increase overall 
antigen-specific responses32. Further studies to understand how dosing and vaccination regimen can be manip-
ulated to control humoral responses both in mice and in NHPs will be very beneficial to the HIV vaccine field. 
Finally, we fully explore the role of liposome composition in stability and quantitatively show the direct impact of 
increased serum stability on germinal center and antibody responses.
Though not evaluated here, liposomes also have the potential for the co-delivery of other antigens or adju-
vants, to boost responses even further. These include, but are not limited to, additional T-cell help cues or cock-
tails of HIV env immunogens to increase both the overall strength and breadth of the immune response against 
HIV variants. Further studies to identify the optimal combination of trimers, particulate delivery, boosting regi-
men, and adjuvant choice will be required in pre-clinical models.
Conclusion
Here we show direct evidence of improved MD39 SOSIP trimer-specific responses in mice by designing stabilized 
liposomes for oriented display of high-density trimers. When immunized with covalent MD39-coupled lipos-
omes, mice had significantly higher GC and antigen-specific Tfh cell responses, resulting in significantly higher 
avidity serum MD39-specific IgG titers compared to those from immunization with soluble MD39. Particulate 
priming was found to be especially important in eliciting eventual high avidity antibody titers, regardless of boost 
immunization with either soluble or particulate trimers. These humoral responses were further improved by 
stabilizing liposomes with the incorporation of sphingomyelin. Together these results show promise for the use of 
HIV env-coupled liposomes as a potential basis of a prophylactic HIV vaccine.
Materials and Methods
Materials. Lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glyce-
ro-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-
glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) (DGS-NTA(Ni)), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide] (sodium 
salt) (MPB) and porcine brain sphingomyelin were purchased from Avanti Polar Lipids (Alabaster, AL). 
Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO). ISCOMATRIX was provided by CSL, Ltd. 
MPLA was purchased from Sigma-Aldrich (St. Louis, MO). Biotinylated 6xHis (Biotin-HHHHHH) and V3 
(TRPNNNTRKSIRIGPGQAFYATG) linear peptides were purchased from Genscript (Piscataway, NJ).
BG505 trimer and antibody production. BG505 SOSIP, MD39-6xHis, MD39-6xHis-Cys and 
MD39-StrepII were prepared as described previously13,18. Briefly, trimer genes were mixed with a plasmid con-
taining furin protease (2 trimer: 1 furin ratio) and 293fectin, then transfected into FreeStyle 293F cells. After seven 
days, the trimers secreted from 293F cells were purified by affinity chromatography using HisTrap or StrepTrap 
HP columns (GE Healthcare) followed by size-exclusion chromatography (SEC) using a S200 Increase column 
(GE Healthcare) in PBS. The molecular weight of the trimer was confirmed by SEC multi-angle light-scattering 
using DAWN HELEOS II and Optilab T-rEX instruments (Wyatt Technology). Broadly neutralizing antibodies 
(VRC01, PGT121, PGT145, PGT151) and non-neutralizing antibodies (B6, 4025, 39F) were produced as IgG 
similar to the trimers, without the addition of furin protease. The antibodies were purified using a Capture Select 
IgG-CH1 column and dialyzed into PBS.
Murine VRC01 chimera antibody sequence was designed by substituting the constant heavy and light chains 
of human VRC0147,48 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CMVR 
VRC01 H, from Dr. John Mascola) with those from mouse IgG2c heavy chain and Ig kappa light chain. Chimeric 
sequences were synthesized as genomic blocks (Integrated DNA Technologies) and cloned into gWIZ expression 
plasmids (Genlantis). Plasmids were transiently transfected into Expi293 cells (ThermoFisher Scientific) using a 
2:3 ratio by mass of the heavy chain and light chain plasmids. Cell culture supernatants were collected at 5 days 
post-transfection and antibody was purified in a ÄKTA pure chromatography system using HiTrap Protein A 
affinity columns (GE Healthcare Life Sciences).
Covalent trimer-conjugated liposome synthesis and characterization. MD39-conjugated lipos-
omes were prepared as previously described with some modifications20. Briefly, unilamellar liposomes com-
prised of phospholipid:cholesterol:DGS-NTA(Ni):MPB lipids in a 61.5:28.5:5:5 mole ratio were synthesized by 
lipid film rehydration and membrane extrusion using a 100 nm membrane at T > Tm(phospholipid) (DMPC = 37 °C, 
DPPC = 50 °C, DSPC = 60 °C), followed by post-synthesis binding of 6xHis-Cys C-terminal-modified trimer 
(MD39-HHHHHHC) for 1 hour at 37 °C in PBS (final concentrations 2.1 µM MD39, 3.53 mM liposomes) fol-
lowed by 16–18 hr incubation at 4 °C with rotation. Non-covalent liposomes were prepared similarly without 
MPB lipid (phospholipid:cholesterol:DGS-NTA(Ni) lipids in a 66.5:28.5:5 mole ratio). Increasingly stabilized 
liposomes were prepared with 15 mole% MPB lipid and with sphingomyelin in place of cholesterol (phospholip-
id:sphingomyelin:DGS-NTA(Ni):MPB lipids in a 51.5:28.5:5:15 mole ratio). For all preparations, unconjugated 
trimer was removed by size exclusion chromatography after coupling using Sepharose CL-2B resin (Sigma).
Total conjugated trimer was quantified by ELISA in the presence of 1% triton-X and 100 mM imidazole to 
fully disrupt liposomes and Ni-6xHis interactions, respectively. Trimer was captured on Nunc MaxiSorp plates 
coated with 2 µg/ml (mouse Fc) VRC01 and detected using 0.2 µg/ml PGT151, followed by secondary detec-
tion with 1:5000 goat anti-human IgG-HRP conjugate. Antigenic profiles were similarly determined by ELISA 
on intact liposomes captured on VRC01-coated plates. Trimer density was calculated using a phospholipid 
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quantification assay (Sigma) to determine the theoretical number of monodisperse, unilamellar liposomes as 
previously described18. Trimer-conjugated liposomes were also characterized by dynamic light scattering and 
cryoelectron microscopy (Jeol 2100 F TEM) in the Swanson Biotechnology Center Nanotechnology Core at the 
Koch Institute, MIT.
Liposome serum stability analysis. Trimer-conjugated liposomes were incubated with 10–20% (final 
concentration) normal mouse serum or PBS (control) for 1–3 days at 37 °C after which released trimer was sep-
arated from liposomes by size exclusion chromatography using Sepharose CL-2B resin. Intact trimer in each 
elution fraction was quantified using PGT151 as the detection antibody as described above. For large liposome 
comparison studies, all samples were initially only run once (n = 1). For all other direct comparison studies, all 
samples were run in triplicate (n = 3).
In vitro B cell activation. VRC01 BCR-expressing Ramos Burkitt’s lymphoma B cells were a gift from Daniel 
Lingwood at the Ragon Institute of MGH, MIT, and Harvard. Cells were stained with 10 µM of the calcium indi-
cator fluo-4 (Thermo Fisher) for 30 minutes in serum-free RPMI prior to activation. Next, 250 µl cells at 1 × 106 
cells/ml were stimulated with either MD39 or MD39-liposomes at indicated concentrations and fluo-4 signal was 
measured by flow cytometry. Cells were pre-warmed to 37 °C and then read for 45 seconds prior to addition of 
MD39 to set a baseline and then read for 4 additional minutes. All flow cytometry was carried out on a BD LSR 
II in the Swanson Biotechnology Center Flow Cytometry Core at the Koch Institute, MIT. For samples where 
activation was measured for longer periods (>5 minutes), fluorescence change over time was measured directly 
using a Tecan fluorescent plate reader. Fluorescent signal was normalized to the baseline signal for each sample. 
All experiments were repeated at least twice.
Synthesis of saponin adjuvant. For some studies, an in-house formulation of a saponin adjuvant was 
utilized. The saponin adjuvant closely resembled ISCOM-like nanoparticles comprised of self-assembled choles-
terol, phospholipid, and Quillaja saponin and was prepared as previously described49; all synthesis was performed 
under sterile conditions with sterile reagents. Briefly, 10 mg each of cholesterol (Avanti Polar Lipids 700000) and 
DPPC (Avanti Polar Lipids 850355) were dissolved separately in 20% MEGA-10 (Sigma D6277) detergent at a 
final concentration of 20 mg/ml and 50 mg Quil-A saponin (InvivoGen vac-quil) was dissolved in MQ H2O at a 
final concentration of 100 mg/ml. Next, DPPC solution was added to cholesterol followed by addition of Quil-A 
saponin in rapid succession and the volume was brought up with PBS for a final concentration of 1 mg/ml choles-
terol and 2% MEGA-10. The solution was allowed to equilibrate at 25 °C overnight, followed by 5 days of dialysis 
against PBS using a 10k MWCO membrane. The adjuvant solution was then filter sterilized using a 0.2 µm Supor 
syringe filter, concentrated using 50k MWCO centricon filters, and further purified by FPLC using a Sephacryl 
S-500 HR size exclusion column. Each adjuvant batch was finally characterized by negative stain TEM and DLS 
to confirm uniform morphology and size and validated for low endotoxin by Limulus Amebocyte Lystae assay 
(Lonza QCL-1000). Final adjuvant concentration was determined by cholesterol quantification (Sigma MAK043).
Immunizations in mice. All procedures used in animal studies were approved by the Committee on Animal 
Care at the Massachusetts Institute of Technology following local, state, and federal regulations. Female balb/c 
mice (6–10 weeks old, Jackson Laboratories) were immunized with 1 µg MD39 trimer either in soluble form or 
conjugated to liposomes mixed with 0.2 U ISCOMATRIX adjuvant (CSL Ltd.) or 5 µg in-house saponin adjuvant, 
unless otherwise noted. For preliminary analysis of V3-specific responses, mice were similarly immunized with 
1 µg wild-type BG505 SOSIP either in soluble form or conjugated to liposomes mixed with 1 µg MPLA (either 
in soluble form or directly in SOSIP liposomes). Liposomes containing MPLA were prepared exactly as above 
by adding MPLA along with the other lipids in the organic solution prior to drying the lipid film (final 0.4 µg/µl 
MPLA in starting 6.45 mM liposome preparation). All mice were immunized subcutaneously with 50 µl trimer/
adjuvant solution in PBS on each side of the tail base. For long-term MD39 trimer immunizations, mice were 
primed on day 0 and boosted at 6 weeks, with weekly retro-orbital blood collection. Blood was collected into 
serum separator tubes and centrifuged at 10,000 × g for 5 min at 4 °C. Sera was stored at −80 °C until analysis.
Germinal center and Tfh analysis. Mice were sacrificed by CO2 inhalation and both inguinal lymph nodes 
were harvested at specified days. Lymph nodes were processed into single-cell suspensions using enzymatic 
digestion with 0.8 mg/ml Collagenase/Dispase and 0.1 mg/ml DNAse (Roche Diagnostics) in complete RPMI 
(with 10% FBS and antibiotics) at 37 °C, followed by passage through a 70-µm cell strainer (BD Biosciences). 
For germinal center analysis, cells were washed with PBS and stained with Live/Dead Aqua (Life Technologies) 
for 15 minutes at 25 °C. Samples were then treated with anti-CD16/32 Fc block (BioLegend), followed by stain-
ing with anti-CD3e-PerCP-Cy5.5 (BD Biosciences), anti-B220-PE-Cy7 (eBioscience), anti-CD138-PE (BD 
Biosciences), anti-IgD-APC (eBioscience), anti-GL7-FITC (BD Biosciences), and PNA-biotin (VectorLabs) 
+ streptavidin-APC-Cy7 (eBioscience) in PBS/1% BSA and finally fixed and stored at 4 °C until analysis. In 
parallel, antigen-specific Tfh analysis was performed as previously described39. Briefly, 1 × 106 cells were stim-
ulated with 5 µg/ml of a BG505 SOSIP-derived overlapping peptide pool for 18 hours at 37 °C. Unstimulated 
cells were run as a control. Cells were then washed and similarly stained with Live/Dead Aqua and treated with 
anti-CD16/32 Fc block, followed by staining with anti-B220-BV510 (BD Biosciences), anti-CD4-PerCP-Cy5.5 
(eBioscience), anti-CD44-AlexaFluor700 (BioLegend), anti-PD1-PE-Cy7 (eBioscience), anti-OX40-APC 
(BioLegend), anti-CD25-FITC (BioLegend), anti-PDL1-BV421 (BioLegend), and purified rat anti-CXCR5 (BD 
Biosciences) + goat anti-rat IgG-biotin (Jackson Immunoresearch) + streptavidin-PE (BioLegend) in PBS/2% 
normal mouse serum/2% FBS/1% BSA and finally fixed and stored at 4 °C until analysis. Flow cytometry was 
carried out on a BD LSR Fortessa.
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Serum ELISAs. Serum anti-BG505 MD39 titers were quantified by ELISA using Nunc MaxiSorp plates 
through a sandwich ELISA designed to preserve MD39 tertiary structure. Plates were coated with 1 µg/ml 
rabbit anti-6xhis (Genscript), blocked with milk block (PBS/5% skim milk/10% goat serum/1% FBS/1% 
BSA/0.2% Tween-20) overnight at 4 °C, and then incubated with 2 µg/ml MD39-6xhis for 2 hours. Mouse sera 
was diluted in milk block starting at 1:50 with 4x serial dilutions and incubated for 2 hours, followed by detec-
tion with 1:5000 goat anti-mouse IgG-HRP conjugate in milk block. For MD39 titer analysis that excluded 
histag responses, plates were instead coated with 2 µg/ml rabbit anti-strepII (Novus Biologicals), blocked with 
PBS/1% BSA overnight at 4 °C, and then incubated with 2 µg/ml MD39-strepII. Mouse sera was diluted in 
PBS/1% BSA starting at 1:50 with 4x serial dilutions and incubated for 2 hours, followed by detection with 
1:5000 goat anti-mouse IgG-HRP conjugate for 1 hour. To determine avidity, ELISAs were conducted simi-
larly using rabbit anti-6xhis to capture MD39-his, since the anti-strepII/MD39-strepII interaction was itself 
disrupted in the presence of urea and could not be used for this analysis. Following serum incubation, plates 
were treated with 4–5 M urea in PBS or PBS alone for 10 minutes at 25 °C followed by several washes before 
detection. Urea and PBS treatment for each individual sample was always conducted on the same plate. Avidity 
indices were calculated as the 100*[(titers in the presence of urea)/(titer in the absence of urea)]. Additionally, 
histag titers were determined by capturing a biotinylated 6xHis peptide at 2 µg/ml onto streptavidin coated 
plates while V3 titers were determined by directly coating V3 linear peptide at 2 µg/ml. For both histag and 
V3 ELISAs, PBS with 1% BSA was used to block and as the diluent for serum and detection antibodies. For all 
titer analyses, all samples being directly compared were run at the same time. All titers reported are inverse 
dilutions where A450nm − A540nm (reference wavelength) equals 0.3.
Statistics. Statistical analyses were performed using GraphPad Prism software. All values and error bars 
are shown as mean ± standard deviation, with the exception of serum titer data that are shown as mean ± 95% 
confidence interval. Titers were analyzed using either the Mann-Whitney test for direct comparisons or a 
Kruskal-Wallis test followed by a Dunn’s post-test for multiple groups. All other data were analyzed using a 
two-tailed unpaired t test to determine statistical significance between two experimental groups or a one-way 
ANOVA followed by a Tukey post-test to compare multiple groups, unless otherwise noted.
Data Availability
All data generated and analyzed during this study are included in this published article (and its Supplementary 
Information files).
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